Logically speaking, it has to help even people who don't have low HDL/Diabetes.  If eGFR is going up and ALPs are coming down in Phase 2 (where there was no specification of low HDL/Diabetes), it is not clear to me why it should only happen with very sick patients.  RVX went for this particular sub set because their data indicated it would be the easiest target group to show efficacy.  It also helps that such a patient group is what the insurance companies are particularly keen to get help on.

But I think the Makalu fellow was right.  If it works for this very sick patient group, it is only a matter of time before the medical profession figures out that it will work for not such a sick population.  And that is why the impact of Apabetalone may well be far bigger than we currently expect.  

But first, as BearAZDown says...we need to get statistically significant MACE relative risk reduction rates, before all this comes true.